A9 Abstracts and the variance-covariance matrix from the model. RESULTS: The advantages of this new approach over the traditional methods are two-fold: 1) The variance of Q-TWiST can be estimated directly, and 2) It is possible to restrict or to compare parameters across different health states. CONCLUSION: Q-TWiST represents a unique quantitative method to simultaneously evaluate the risks and benefits of treatment on successive health states. We present a single survival model that addresses data censoring, covariate adjustment and variance estimation. This new approach provides opportunities for expanded use of the QTWiST method beyond the clinical trial such that application to observational studies is possible. 3 Imperial College, School of Medicine, London, UK OBJECTIVE: The Overactive Bladder Questionnaire (OAB-q) assesses symptom bother and health-related quality of life (HRQL) among patients with overactive bladder (OAB) and has been shown to be reliable, valid, and responsive. The purpose of this analysis was to establish the instrument's minimally important difference (MID), which is the smallest difference in score that patients perceive as beneficial. METHODS: Data were from four clinical trials (1 US, 3 international), totaling 3426 patients. All trials involved 12 weeks of tolterodine treatment. Distribution-based (e.g., effect size, standard error of measurement (SEM), and half-standard deviation) and anchor-based approaches were used. RESULTS: The mean age of the 4 trial samples ranged from 58.7 to 61.3 years. Patients were predominantly female (65.0%) and Caucasian (87.8%). At baseline, half-standard deviation of the OAB-q Symptom Bother subscale ranged from 9.4 to 9.9, and SEM ranged from 7.00 to 7.28. Half-standard deviation of the HRQL subscales (Coping, Concern, Sleep, and Social Interaction) ranged from 9.8 to 15.6, with SEM ranging from 6.8 to 8.3. The OAB-q subscales had moderate to large effect sizes in all trials, with Symptom Bother having the largest effect sizes (range = -0.61 to -1.23). Anchorbased analyses found significantly greater OAB-q change scores were associated with greater patient perceived treatment benefit and satisfaction. The difference between change scores of patients perceiving "no benefit" and "little benefit" ranged from 6.9 to 16.8 for all scales except Social Interaction (4.3 to 7.8), with the majority of differences greater than 10 points (possible subscale scores range from 0 to 100). Greater OAB-q change scores were associated with greater improvements in micturition diary variables. CONCLUSIONS: Multiple methodologies provide strong justification for recommendation of a 10-point MID for all OAB-q subscales. This MID may be conservative for some subscales, however a uniform MID is recommended to facilitate instrument use and interpretation. 
QL2 TESTING THE CROSS-WALK: SALVAGING CANCER SPECIFIC MEASURES FOR USE IN ECONOMIC EVALUATION
Wilson TR 1 , Kind P 2 1 University of York, York, UK; 2 Outcomes Research Group, York, UK
OBJECTIVES:
Clinical trials often include condition-specific measures that lack the attributes required for economic evaluation. This study reports on the investigation of models for estimating EQ-5D index (a generic, utility-weighted index of health status) from FACT-G and QLQ-C30 (two widely used cancerspecific measures.) METHODS: As part of an observational study in colorectal cancer FACT-G, QLQ-C30 and EQ-5D were administered to 223 patients in an NHS hospital one week after discharge following surgery. Alternative models for estimating EQ-5D index from the items of both cancer-specific questionnaires were evaluated. Items were treated as both continuous data or were dichotomised. These were entered as independent variables in a series of stepwise linear regression analyses with EQ-5D index as the dependent variable. Criteria for comparing model performance were pre-specified and included explained variance (r 2 ), Pearson correlation co-efficient (r) and mean absolute difference. RESULTS: More than 55% of the variance was explained by the model which employed continuous items and the estimated EQ-5D index correlated well with actual scores (r > 0.65). Items from FACT-G and QLQ-C30 performed equally well in this model. Less variance was explained by the model using dichotomised items (r 2 > 0.40) and the correlation between estimated and actual EQ-5D index was less pronounced (r > 0.45). Items from QLQ-C30 performed better than those from FACT-G in this model, but altering the cut-point to dichotomise the items had an appreciable effect on explained variance. Despite moderate to good correlation between actual and estimated EQ-5D index in both models, the mean absolute difference between these scores gave some cause for concern. CONCLUSIONS: Despite differences in item content, both QLQ-C30 and FACT-G generate viable estimates of EQ-5D. This is an important finding that allows for the conversion of data from studies where direct comparison is otherwise impossible. However, the technique requires further refinement so as to improve its performance. METHODS: 221 patient-carrier pairs stratified by age and gender were randomly selected from 14 dialysis units: 152 hemodialysis-69 peritoneal dialysis. Patients' HRQoL was evaluated by patient and FAM, NUR and PH using EQ-5D (dimensions and Visual Analogue Scale-VAS). Patients and FAM answered the SF-36 (PCS-MCS) and Duke-UNK Functional Social Support (FSS). FAM also answered Caregiver Burden Interview of Zarit (ZS); PH, the co-morbidity Index of patients; and NUR, patient's dependence in daily activities using the Barthel Scale (BS). RESULTS: The correlation coefficients between the VAS of the patients and their carriers were 0.42 (FAM), 0.49 (NUR) and 0.30 (PH); NUR and PH scored VAS higher than patients (p < 0.01). The agreement (Kappa) between EQ-5D dimension scores varied between moderate for Mobility (0.56-FAM; 0.55-NUR; 0.47-PH) and Self-Care (0.48-FAM; 0.50-NUR; 0.42-PH) and low or insignificant for Pain (0.32-FAM; 0.40-NUR; 0.18-PH) and Anxiety/Depression (0.26-FAM; 0.28-NUR; 0.14-PH). The variables associated to the difference between the VAS score of patient and carriers were studied using lineal regression. Mean (S.D) PCS and MCS of caregivers were 48.4 (13.8) and 48.0 (11.3). Multiple regression analysis showed that higher ZS and older patient age were associated to lower PCS of the caregiver (R2 = 0.15; p < 0.001) and that higher ZS and lower FSS of the caregiver, and lower MCS of the patient were associated to lower MCS of the caregiver (R2 = 0.29; p < 0.001). Lower FSS, PCS and MCS of the caregiver and higher age and lower PCS and MCS of the patient were associated to higher score on ZS of caregivers (R2 = 0.49; p < 0.001). CON-CLUSIONS: Agreement between patients and carriers was moderate for "objective" dimensions of HRQOL and low for "subjective" ones. HRQoL of FAM is slightly worse than that of the general population. 
QL3 "FAMIDIAL STUDY": ANALYSIS OF THE DIFFERENCES BETWEEN DIALYSIS PATIENTS AND THEIR CAREGIVERS (FAMILY CARERS, NURSES AND DOCTORS) ON DIALYSIS PATIENTS' HRQOL, AND OF THE FAMILY CARERS' HRQOL AND BURDEN

Alvarez
NSCLC). METHODS:
We conducted a detailed search of the published literature on quality of life, NSCLC, and chemotherapy, excluding studies with limited total sample size (<50). Thirty-five studies covering 10 QoL questionnaires and 17 chemotherapy drugs were reviewed. RESULTS: Most studies were conducted in Europe (primarily Italy and the U.K.), and the average sample size was 137 patients per treatment arm (range: 16, 406). QoL questionnaires were typically self-administered at baseline and every 3 weeks thereafter until disease progression (roughly 2 years duration). The EORTC QLQ-C30 and EORTC QLQ-LC13 (QLQ-LC13) questionnaires were most often used in Europe (15 of 24 European studies); however, the FACT-L questionnaire was commonly used in the U.S. (7 of 13 U.S. studies). The EORTC QLQ-C30/QLQ-LC13 combination detected significant differences for QoL outcomes in 14 of 15 studies which reported EORTC domain scores, while the FACT-L detected differences in 3 of 7 studies. Both questionnaires contain similar domains, but the EORTC QLQ-C30/QLQ-LC13 includes more items on chemotherapy symptoms and FACT-L includes items on patients' attitude towards their cancer. Several studies examined potential non-random bias due to missing data resulting from death or disease progression. One study detected conflicting results when including (versus excluding) missing data from their analyses. Another study observed different QoL results when comparing cycle-to-cycle data at similar time points rather than study completion data using the last observation carried forward. CONCLUSIONS: Although EORTC QLQ-C30/QLQ-LC13 and FACT-L are both widely used, are similar in content, and can detect differences in NSCLC patients, they are used preferentially in Europe and the U.S, respectively. Inappropriate assumptions concerning the randomness of missing data can result in biased estimates of QoL.
Cost Evaluation Studies in Interventional Cardiology
IC1 THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS BASED ON THE A SYNTHESIS OF THE RESULTS OF 15 RANDOMISED CONTROLLED TRIALS
Hawkins N, Sculpher M University of York, York, UK OBJECTIVES: To inform coverage decisions regarding drugeluting coronary stents by assessing their cost-effectiveness for particular high-risk patient subgroups. METHODS: The analysis compared the cost-effectiveness of the two drug eluting stents (DES) available in the UK (Cypher and Taxus) and bare-metal stents (BMS). A review was undertaken of randomised trials including one or both of the DES. Individual patient data were available for some of these trials. The model parameters extracted from the trials were further revascularisation rates, undertaken for clinical reasons, either percutaneous interventions or bypass surgery, during follow-up. Three subgroups were considered on the basis of their higher baseline risk of repeat revascularisation: small vessels, long lesions and diabetics; a fourth subgroup without these risk factors was also considered. The evidence synthesis was implemented as a Bayesian hierarchical logistic model. A probabilistic decision model was developed. RESULTS: Evidence from 15 trials was incorporated into the synthesis, 5 of which supplied individual patient data. The probability of repeat percutaneous interventions was lowest with Cypher and highest with BMS. Both DES had lower probabilities of subsequent bypass surgery than BMS, and the probability for Taxus was slightly lower than for Cypher. Cost-effectiveness results were sensitive to the stent prices. At current UK prices (£908 BMS, £1300 Taxus, £1341 Cypher), Taxus is dominated by Cypher in diabetic patients and subject to extended dominance in all other subgroups. Cypher has an incremental cost per QALY gained, compared to BMS, of £13,759, £23,086, £13,740 in patients with small vessels, long lesions and diabetes, respectively. In patients with no risk factors, this increases to £35,865. CONCLUSIONS: Given existing list prices, Cypher is likely to be considered more cost-effective than BMS and Taxus in patients at high baseline risk of further revascularization. This conclusion may change following any changes in the relative stent prices. 3 Medtronic AG, Tolochenaz, Switzerland OBJECTIVES: Endeavor combines the Driver stent, the drug ABT-578 and a PC polymer into a new drug-eluting coronary artery stent (DES) system. As results from long-term trials of Endeavor are not yet available, economic modeling techniques must be employed to evaluate the cost-effectiveness of this new treatment option. The study undertook the first assessment of the cost-effectiveness of Endeavor DES, compared to the Driver bare-metal stent (BMS), in the treatment of de novo lesions in native coronary arteries. METHODS: A Markov model was developed simulating the results of the ENDEAVOR II trial at nine months follow-up, and extrapolating to five years using the BENESTENT I trial. No difference was assumed between the outcomes with the two stents after the first year. The events modeled were target vessel revascularisations, AMIs, cere-
IC2 PREDICTING THE COST-EFFECTIVENESS OF THE ABT-578 COATED DRIVER CORONARY STENT (ENDEAVOR) IN DE NOVO NATIVE CORONARY ARTERY LESIONS
